• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

意大利一家三级护理大学医院的感染情况:一项回顾性分析。

Infection in an Italian Tertiary Care University Hospital: A Retrospective Analysis.

作者信息

Medaglia Alice Annalisa, Mancuso Alessandro, Albano Chiara, Zinna Giuseppe, Pipitò Luca, Calà Cinzia, Immordino Rita, Rubino Raffaella, Bonura Silvia, Canino Baldassare, Calamusa Giuseppe, Colomba Claudia, Almasio Pier Luigi, Cascio Antonio

机构信息

Infectious and Tropical Diseases Unit, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.

Antimicrobial Stewardship Team, AOU Policlinico "P. Giaccone", 90127 Palermo, Italy.

出版信息

Antibiotics (Basel). 2023 Apr 30;12(5):837. doi: 10.3390/antibiotics12050837.

DOI:10.3390/antibiotics12050837
PMID:37237740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10215700/
Abstract

infection (CDI) is a significant cause of morbidity and mortality, mostly in frail patients. Notification is not mandatory in Italy, and data on incidence, risk of death, and recurrence are lacking. The purpose of this study was to determine CDI incidence and risk factors for mortality and recurrence. The "ICD-9 00845" code in hospital-standardized discharged forms (H-SDF) and microbiology datasets were used to retrieve CDI cases at Policlinico Hospital, Palermo between 2013 and 2022. Incidence, ward distribution, recurrence rate, mortality, and coding rate were considered. The risk of death and recurrence was predicted through multivariable analysis. There were 275 CDIs, 75% hospital-acquired, the median time between admission and diagnosis was 13 days, and the median stay was 21 days. Incidence increased from 0.3 to 5.6% (an 18.7-fold increase) throughout the decade. Only 48.1% of cases were coded in H-SDF. The rate of severe/severe-complicated cases increased 1.9 times. Fidaxomicin was used in 17.1% and 24.7% of cases overall and since 2019. Overall and attributable mortalities were 11.3% and 4.7%, respectively. Median time between diagnosis and death was 11 days, and recurrence rate was 4%. Bezlotoxumab was administered in 64% of recurrences. Multivariable analysis revealed that only hemodialysis was associated with mortality. No statistically significant association in predicting recurrence risk emerged. We advocate for CDI notification to become mandatory and recommend coding CDI diagnosis in H-SDF to aid in infection rate monitoring. Maximum attention should be paid to preventing people on hemodialysis from getting CDI.

摘要

艰难梭菌感染(CDI)是发病和死亡的重要原因,主要发生在体弱患者中。在意大利,报告并非强制性的,因此缺乏发病率、死亡风险和复发率的数据。本研究的目的是确定CDI的发病率以及死亡和复发的风险因素。利用医院标准化出院表格(H-SDF)中的“ICD-9 00845”代码和微生物学数据集,检索了2013年至2022年期间巴勒莫Policlinico医院的CDI病例。考虑了发病率、病房分布、复发率、死亡率和编码率。通过多变量分析预测死亡和复发风险。共有275例CDI,75%为医院获得性感染,入院至诊断的中位时间为13天,中位住院时间为21天。在这十年间,发病率从0.3%增至5.6%(增长了18.7倍)。H-SDF中仅对48.1%的病例进行了编码。严重/严重复杂病例的比例增加了1.9倍。总体病例中17.1%以及自2019年以来24.7%的病例使用了非达霉素。总体死亡率和归因死亡率分别为11.3%和4.7%。诊断至死亡的中位时间为11天,复发率为4%。64%的复发病例使用了贝佐托昔单抗。多变量分析显示,只有血液透析与死亡率相关。在预测复发风险方面未发现具有统计学意义的关联关系。我们主张将CDI报告设为强制性,并建议在H-SDF中对CDI诊断进行编码,以协助监测感染率。应特别注意预防血液透析患者发生CDI。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/d267852414a1/antibiotics-12-00837-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/7c4bb961468e/antibiotics-12-00837-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/dfa0edbf7094/antibiotics-12-00837-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/5275a152f1bb/antibiotics-12-00837-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/7aa488620474/antibiotics-12-00837-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/a03e9bf12227/antibiotics-12-00837-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/d267852414a1/antibiotics-12-00837-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/7c4bb961468e/antibiotics-12-00837-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/dfa0edbf7094/antibiotics-12-00837-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/5275a152f1bb/antibiotics-12-00837-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/7aa488620474/antibiotics-12-00837-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/a03e9bf12227/antibiotics-12-00837-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebef/10215700/d267852414a1/antibiotics-12-00837-g006.jpg

相似文献

1
Infection in an Italian Tertiary Care University Hospital: A Retrospective Analysis.意大利一家三级护理大学医院的感染情况:一项回顾性分析。
Antibiotics (Basel). 2023 Apr 30;12(5):837. doi: 10.3390/antibiotics12050837.
2
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.欧洲临床微生物学和传染病学会:成人艰难梭菌感染治疗指南的 2021 年更新。
Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21. doi: 10.1016/j.cmi.2021.09.038. Epub 2021 Oct 20.
3
Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study.瑞士一家三级保健医院治疗艰难梭菌感染的结果:一项观察性研究。
Swiss Med Wkly. 2020 Jan 15;150:w20173. doi: 10.4414/smw.2020.20173.
4
Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of () Infection.贝佐妥昔单抗在接受甲硝唑、万古霉素或非达霉素治疗()感染的参与者中的疗效。
Open Forum Infect Dis. 2020 Jun 2;7(6):ofaa157. doi: 10.1093/ofid/ofaa157. eCollection 2020 Jun.
5
Effectiveness of Bezlotoxumab for Prevention of Recurrent Infection Among Transplant Recipients.贝佐妥单抗预防移植受者反复感染的有效性。
Open Forum Infect Dis. 2021 Jun 4;8(7):ofab294. doi: 10.1093/ofid/ofab294. eCollection 2021 Jul.
6
Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.非达霉素与万古霉素或甲硝唑用于艰难梭菌感染住院治疗的真实世界预算影响
Antibiotics (Basel). 2023 Jan 6;12(1):106. doi: 10.3390/antibiotics12010106.
7
Real-world Experience of Bezlotoxumab for Prevention of Infection: A Retrospective Multicenter Cohort Study.贝佐妥单抗预防感染的真实世界经验:一项回顾性多中心队列研究。
Open Forum Infect Dis. 2020 Mar 19;7(4):ofaa097. doi: 10.1093/ofid/ofaa097. eCollection 2020 Apr.
8
Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.在美国,非达霉素与万古霉素治疗艰难梭菌感染的预算影响分析。
Infect Dis Ther. 2022 Feb;11(1):111-126. doi: 10.1007/s40121-021-00480-0. Epub 2021 Jul 22.
9
Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. fidaxomicin 与甲硝唑、万古霉素及其联合治疗首发、首次复发和严重艰难梭菌感染的疗效比较:一项观察性队列研究。
Int J Infect Dis. 2021 Feb;103:226-233. doi: 10.1016/j.ijid.2020.11.004. Epub 2020 Nov 11.
10
Recurrent Clostridioides difficile infections in solid organ transplant recipients: The international CALIPSO study.实体器官移植受者中艰难梭菌反复感染:国际CALIPSO研究
J Infect. 2024 Dec;89(6):106306. doi: 10.1016/j.jinf.2024.106306. Epub 2024 Oct 5.

引用本文的文献

1
Infections: Epidemiological and Laboratory Data from the Internal Medicine Departments of a Tertiary Care Hospital in Athens, Greece, During the Past Decade.感染:希腊雅典一家三级护理医院内科过去十年的流行病学和实验室数据。
Medicina (Kaunas). 2025 Aug 5;61(8):1416. doi: 10.3390/medicina61081416.
2
Clostridioides difficile infections caused by hypervirulent strains: a single-centre real-life study.由高毒力菌株引起的艰难梭菌感染:一项单中心真实世界研究。
Eur J Clin Microbiol Infect Dis. 2025 Jan;44(1):99-107. doi: 10.1007/s10096-024-04982-w. Epub 2024 Nov 11.
3
Infection: Use of Inflammatory Biomarkers and Hemogram-Derived Ratios to Predict Mortality Risk in Hospitalized Patients.

本文引用的文献

1
Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.贝洛妥珠单抗预防艰难梭菌感染复发的疗效:一项意大利多中心队列研究。
Int J Infect Dis. 2023 Jun;131:147-154. doi: 10.1016/j.ijid.2023.04.004. Epub 2023 Apr 7.
2
Intravenous metronidazole for fulminant Clostridioides difficile infection.静脉注射甲硝唑治疗暴发性艰难梭菌感染。
Clin Microbiol Infect. 2023 May;29(5):656-657. doi: 10.1016/j.cmi.2023.01.026. Epub 2023 Feb 3.
3
Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).
感染:使用炎症生物标志物和血常规衍生比值预测住院患者的死亡风险
Antibiotics (Basel). 2024 Aug 15;13(8):769. doi: 10.3390/antibiotics13080769.
4
Management of Clostridioides difficile infection: an Italian Delphi consensus.艰难梭菌感染的管理:意大利德尔菲共识。
J Antimicrob Chemother. 2024 Sep 3;79(9):2103-2118. doi: 10.1093/jac/dkae179.
艰难梭菌感染(CDI):一项泛欧洲多中心成本与资源利用研究,欧洲艰难梭菌感染抗菌耐药性研究(COMBACTE-CDI)的结果
Clin Microbiol Infect. 2023 May;29(5):651.e1-651.e8. doi: 10.1016/j.cmi.2022.12.019. Epub 2022 Dec 29.
4
Fidaxomicin for the Treatment of Infection in Adult Patients: An Update on Results from Randomized Controlled Trials.非达霉素用于治疗成年患者感染:随机对照试验结果的最新进展
Antibiotics (Basel). 2022 Oct 6;11(10):1365. doi: 10.3390/antibiotics11101365.
5
Prevalence and trends of infection among persons requiring maintenance hemodialysis: A systematic review and meta-analysis.需要维持性血液透析患者的感染患病率和趋势:系统评价和荟萃分析。
Infect Control Hosp Epidemiol. 2023 Jul;44(7):1068-1075. doi: 10.1017/ice.2022.217. Epub 2022 Sep 23.
6
Comparison of trends in infections in hospitalised patients during the first and second waves of the COVID-19 pandemic: A retrospective sentinel surveillance study.新冠疫情第一波和第二波期间住院患者感染趋势的比较:一项回顾性哨点监测研究。
Lancet Reg Health Eur. 2022 Aug;19:100424. doi: 10.1016/j.lanepe.2022.100424. Epub 2022 Jun 28.
7
Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees.美国医疗保险优势计划参保者中艰难梭菌感染的发病率、归因死亡率,以及医疗保健和自付费用。
Clin Infect Dis. 2023 Feb 8;76(3):e1476-e1483. doi: 10.1093/cid/ciac467.
8
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.欧洲临床微生物学和传染病学会:成人艰难梭菌感染治疗指南的 2021 年更新。
Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21. doi: 10.1016/j.cmi.2021.09.038. Epub 2021 Oct 20.
9
Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review.严重且复发艰难梭菌感染的预后因素:系统评价。
Clin Microbiol Infect. 2022 Mar;28(3):321-331. doi: 10.1016/j.cmi.2021.09.026. Epub 2021 Oct 14.
10
Impact of COVID-19 prevention measures on infections in a regional acute care hospital.新冠疫情防控措施对某地区急症医院感染情况的影响
Exp Ther Med. 2021 Nov;22(5):1215. doi: 10.3892/etm.2021.10649. Epub 2021 Aug 26.